Conduct Disorder

Categories: Mental diseases

Aliases & Classifications for Conduct Disorder

MalaCards integrated aliases for Conduct Disorder:

Name: Conduct Disorder 12 74 54 43 15 17 71


External Ids:

Disease Ontology 12 DOID:12995
ICD9CM 34 312.9
MeSH 43 D019955
NCIt 49 C89329
SNOMED-CT 67 430909002
ICD10 32 F91 F91.9
UMLS 71 C0149654

Summaries for Conduct Disorder

Disease Ontology : 12 A specific developmental disorder marked by a pattern of repetitive behavior wherein the rights of others or social norms are violated.

MalaCards based summary : Conduct Disorder is related to oppositional defiant disorder and impulse control disorder. An important gene associated with Conduct Disorder is MAOA (Monoamine Oxidase A), and among its related pathways/superpathways are Transmission across Chemical Synapses and Circadian entrainment. The drugs Oxcarbazepine and Aripiprazole have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Conduct disorder (CD) is a mental disorder diagnosed in childhood or adolescence that presents itself... more...

Related Diseases for Conduct Disorder

Diseases related to Conduct Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 323)
# Related Disease Score Top Affiliating Genes
1 oppositional defiant disorder 32.7 SLC6A4 SLC6A3 MAOA DRD4 DRD2 DBH
2 impulse control disorder 32.7 SLC6A4 SLC6A3 MAOA DRD5 DRD4 DRD2
3 depression 31.2 TPH1 SLC6A4 MAOA
4 personality disorder 30.9 TPH1 SLC6A4 SLC6A3 MAOA DRD4 DRD2
5 avoidant personality disorder 30.9 TPH1 SLC6A4 SLC6A3 MAOA DRD4
6 antisocial personality disorder 30.8 SLC6A4 SLC6A3 MAOA GABRA2 DRD4 DRD2
7 alcohol use disorder 30.6 SLC6A4 SLC6A3 GABRA2 DRD2 COMT ALDH2
8 drug dependence 30.6 SLC6A4 SLC6A3 POMC GABRA2 DRD2
9 cannabis abuse 30.5 DRD4 DRD2 COMT
10 borderline personality disorder 30.5 TPH1 SLC6A4 SLC6A3 MAOA DRD2 COMT
11 brunner syndrome 30.4 TPH1 SLC6A4 MAOA COMT
12 attention deficit-hyperactivity disorder 30.3 TPH1 SLC6A4 SLC6A3 MAOA DRD5 DRD4
13 bipolar i disorder 30.2 SLC6A4 DRD4 DRD2 COMT
14 separation anxiety disorder 30.2 SLC6A4 SLC6A3 NBAS DRD4
15 schizoaffective disorder 30.2 SLC6A4 DRD4 DRD2 COMT
16 agoraphobia 30.2 SLC6A4 NBAS MAOA COMT
17 social phobia 30.2 SLC6A4 NBAS MAOA DRD2 COMT
18 sleep disorder 30.2 SLC6A4 SLC6A3 POMC DRD2
19 post-traumatic stress disorder 30.2 SLC6A4 POMC MAOA DRD2 DBH COMT
20 tardive dyskinesia 30.1 DRD2 COMT
21 asperger syndrome 30.1 SLC6A4 OXTR COMT
22 opiate dependence 30.1 TPH1 SLC6A4 SLC6A3 POMC DRD4 DRD2
23 obsessive-compulsive personality disorder 30.1 SLC6A4 COMT
24 mood disorder 30.1 TPH1 SLC6A4 SLC6A3 POMC MAOA DRD4
25 mental depression 30.1 TPH1 SLC6A4 SLC6A3 POMC OXTR MAOA
26 generalized anxiety disorder 30.0 TPH1 SLC6A4 SLC6A3 MAOA DRD2 COMT
27 melancholia 30.0 SLC6A4 POMC MAOA
28 intermittent explosive disorder 30.0 SLC6A4 MAOA DRD2 COMT
29 postpartum depression 30.0 SLC6A4 POMC OXTR MAOA COMT
30 alexithymia 30.0 SLC6A4 OXTR DRD2 COMT
31 traumatic brain injury 30.0 DRD2 COMT
32 anxiety 30.0 TPH1 SLC6A4 SLC6A3 POMC OXTR MAOA
33 major depressive disorder 30.0 TPH1 SLC6A4 SLC6A3 POMC OXTR MAOA
34 substance abuse 29.7 SLC6A4 SLC6A3 POMC MAOA GABRA2 DRD5
35 eating disorder 29.6 SLC6A4 SLC6A3 POMC OXTR DRD2 COMT
36 tic disorder 29.6 SLC6A4 SLC6A3 MAOA DRD5 DRD4 DRD2
37 anorexia nervosa 29.6 TPH1 SLC6A4 POMC MAOA DRD4 COMT
38 bipolar disorder 29.6 TPH1 SLC6A4 SLC6A3 MAOA GABRA2 DRD5
39 arrhythmogenic right ventricular dysplasia, familial, 5 29.6 PITRM1 C5orf15
40 pervasive developmental disorder 29.5 SLC6A4 SLC6A3 OXTR MAOA DRD5 DRD4
41 alcohol dependence 29.4 TPH1 SLC6A4 SLC6A3 POMC MAOA GABRA2
42 obsessive-compulsive disorder 29.4 TPH1 SLC6A4 SLC6A3 POMC OXTR MAOA
43 panic disorder 29.3 TPH1 SLC6A4 SLC6A3 POMC MAOA DRD5
44 substance dependence 29.3 TPH1 SLC6A4 SLC6A3 POMC MAOA GABRA2
45 autism spectrum disorder 29.3 SLC6A4 SLC6A3 POMC OXTR MAOA GABRA2
46 psychotic disorder 29.2 TPH1 SLC6A4 SLC6A3 MAOA DRD5 DRD4
47 gilles de la tourette syndrome 29.2 SLC6A4 SLC6A3 MAOA DRD5 DRD4 DRD2
48 tobacco addiction 29.1 TPH1 SLC6A4 SLC6A3 MAOA GABRA2 DRD5
49 autism 29.0 TPH1 SLC6A4 SLC6A3 POMC OXTR MAOA
50 disease of mental health 28.9 SLC6A4 SLC6A3 POMC MAOA DRD5 DRD4

Comorbidity relations with Conduct Disorder via Phenotypic Disease Network (PDN):

Acute Cystitis Alzheimer Disease
Deficiency Anemia Schizophreniform Disorder

Graphical network of the top 20 diseases related to Conduct Disorder:

Diseases related to Conduct Disorder

Symptoms & Phenotypes for Conduct Disorder

GenomeRNAi Phenotypes related to Conduct Disorder according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00106-A-0 10.02 MAOA
2 Decreased viability GR00221-A-1 10.02 GABRA2
3 Decreased viability GR00221-A-2 10.02 GABRA2
4 Decreased viability GR00221-A-4 10.02 GABRA2
5 Decreased viability GR00240-S-1 10.02 C5orf15 COMT
6 Decreased viability GR00249-S 10.02 C1QTNF7 COMT NTSR2 SLC6A4 TPH1
7 Decreased viability GR00381-A-1 10.02 C5orf15 NTSR2 SLC6A4
8 Decreased viability GR00381-A-3 10.02 SLC6A4
9 Decreased viability GR00386-A-1 10.02 ALDH2 C1QTNF7 COMT DBH NTSR2 POMC
10 Decreased viability GR00402-S-2 10.02 NTSR2 OXTR
11 Increased the percentage of infected cells GR00402-S-1 8.32 TOX2

MGI Mouse Phenotypes related to Conduct Disorder:

# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.3 ALDH2 COMT DBH DRD2 DRD4 DRD5
2 cardiovascular system MP:0005385 10.06 ALDH2 COMT DBH DRD2 DRD5 GABRA2
3 homeostasis/metabolism MP:0005376 10 ALDH2 C1QTNF7 COMT DBH DRD2 DRD4
4 endocrine/exocrine gland MP:0005379 9.96 ALDH2 COMT DBH DRD2 DRD5 OXTR
5 integument MP:0010771 9.65 ALDH2 DBH DRD2 GABRA2 NTSR2 OXTR
6 nervous system MP:0003631 9.5 ALDH2 COMT DBH DRD2 DRD4 DRD5

Drugs & Therapeutics for Conduct Disorder

Drugs for Conduct Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 42)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Oxcarbazepine Approved Phase 4 28721-07-5 34312
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
Amphetamine Approved, Illicit, Investigational Phase 4 300-62-9 5826 3007
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
9 Sodium Channel Blockers Phase 4
10 Diuretics, Potassium Sparing Phase 4
11 Anticonvulsants Phase 4
12 Antidepressive Agents Phase 4
13 Dopamine agonists Phase 4
14 Serotonin Receptor Agonists Phase 4
15 Serotonin 5-HT1 Receptor Agonists Phase 4
16 adderall Phase 4
17 Adrenergic Agents Phase 4
18 Sympathomimetics Phase 4
19 Atomoxetine Hydrochloride Phase 4
20 Psychotropic Drugs Phase 4
21 Antipsychotic Agents Phase 4
22 Dopamine Agents Phase 4
23 Dopamine Antagonists Phase 4
24 Neurotransmitter Agents Phase 4
25 Central Nervous System Stimulants Phase 4
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
Lithium carbonate Approved Phase 3 554-13-2
Ethanol Approved Phase 2, Phase 3 64-17-5 702
Nicotine Approved Phase 3 54-11-5 942 89594
Ziprasidone Approved Phase 2 146939-27-7 60854
Oxytocin Approved, Vet_approved Phase 2 50-56-6 53477758 439302
Brexpiprazole Approved, Investigational Phase 1 913611-97-9 11978813
Testosterone Approved, Experimental, Investigational 58-22-0, 481-30-1 10204 6013
Cocaine Approved, Illicit Early Phase 1 50-36-2 446220 5760
tannic acid Approved 1401-55-4
Benzocaine Approved, Investigational 94-09-7, 1994-09-7 2337
37 Omega 3 Fatty Acid
38 Hormones
39 Complement System Proteins
40 Cholinergic Agents
41 Nicotinic Agonists
42 Pharmaceutical Solutions

Interventional clinical trials:

(show top 50) (show all 113)
# Name Status NCT ID Phase Drugs
1 Adjunctive Treatment With Divalproex or Risperidone for Aggression Refractory to Stimulant Monotherapy Among Children With ADHD Unknown status NCT00794625 Phase 4 Valproate;Risperidone;Placebo;Stimulant medication
2 A Multi-center, Randomized, Double-blind, Cross-over, Placebo-controlled Clinical Trial to Evaluate Efficacy and Safety of Oxcarbazepine p.o. (300-1200 mg/Day) as Adjuvant Therapy for Impulsivity and Aggressive Behavior in Conduct Disorders in Adolescents Completed NCT00154362 Phase 4 Oxcarbazepine
3 Early Primary Prevention of Conduct Problems Completed NCT00051714 Phase 4
4 Open Label Trial of Aripiprazole in the Treatment of CD in Adolescents Completed NCT00250705 Phase 4 Aripiprazole
5 Double-Blind, Placebo-Controlled Trial of Flexible Dose Divalproex Sodium Adjunctive to Stimulant Treatment for Aggressive Children With Attention-Deficit Hyperactivity Disorder Completed NCT00228046 Phase 4 Divalproex Sodium;Methylphenidate;Dextroamphetamine;Mixed Amphetamine Salts
6 Stimulant and Risperidone in Children With Severe Physical Aggression Completed NCT00796302 Phase 4 Methylphenidate HCl;Risperidone;Placebo
7 Double Blind Placebo Controlled Study of Depakote (Divalproex Sodium) in Children With Temper Outbursts and Severe Mood Swings Completed NCT02078596 Phase 4 Divalproex
8 Brain Indices of Stimulant Treatment in Drug-Naive Youth at Risk for Substance Use Disorder Active, not recruiting NCT04170738 Phase 4 Adderall
9 Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk Active, not recruiting NCT03781765 Phase 4 Methylphenidate;Atomoxetine
10 The Assessment of Efficacy and Tolerability of Methylphenidate vs. Risperidone in the Treatment of Children and Adolescents With ADHD and Disruptive Disorders Terminated NCT02063945 Phase 4 Methylphenidate;Risperidone
11 Multidimensional Treatment Foster Care for Adolescents Withdrawn NCT01726361 Phase 4
12 Long-Term Lithium for Aggressive Conduct Disorder Completed NCT00000385 Phase 3 Lithium;Placebo
13 The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder and Other Disruptive Behavior Disorders In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years Completed NCT00266552 Phase 3 risperidone
14 The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years Completed NCT00250354 Phase 3 Risperidone oral solution
15 RCT of an Animal-Assisted Intervention With Adjudicated Youth Completed NCT01594606 Phase 3
16 Effects of Risperidone on Cognitive-Motor Performance and Motor Movements in Chronically Medicated Children Completed NCT00399698 Phase 3 Risperdal
17 A New School-based Drug Prevention Programme for Teenagers: Interventions That Target Personality Risk for Substance Abuse and Mental Illness Completed NCT00344474 Phase 2, Phase 3
18 Treating Tobacco Dependence in Adolescents With Co-occurring Psychiatric Disorders Completed NCT00618943 Phase 3
19 Cognitive Behavioral Interventions That Target Personality Risk for Substance Abuse and Mental Illness: Delivery by Educational Professionals Completed NCT00776685 Phase 2, Phase 3
20 Prospective Study the Adolescent Inpatients Rehabilitation Terminated NCT01709526 Phase 2, Phase 3
21 Home-based Behavioral Therapy (HBT): Psychosocial Intervention Project for Early Adolescents With Pre- or Early Substance Use Disorder: Phase II Completed NCT00280228 Phase 2
22 A Randomized, Multicenter, Parallel Group, Dose-Ranging Study to Evaluate the Safety and Tolerability of SPN-810 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and Persistent Serious Conduct Problems Completed NCT00626236 Phase 2 SPN-810;SPN-810;SPN-810;SPN-810
23 Preventive Intervention for Mexican American Adolescents Completed NCT00051727 Phase 2
24 Evaluation of a Group-based, Cognitive-behavioural Intervention With Former Child Soldiers and Other War-affected Children in the Democratic Republic of Congo: A Randomised Controlled Trial. Completed NCT01494831 Phase 2
25 Ziprasidone for Severe Conduct and Other Disruptive Behavior Disorders in Children and Adolescents - a Placebo Controlled, Randomized, Double Blind Clinical Trial Completed NCT00676429 Phase 2 Ziprasidone Hydrochloride;Placebo
26 Investigating the Impact of Oxytocin on Irritability/Emotional Dysregulation in Children and Adolescents With Disruptive Behavior and Mood Disorders, and the Possible Mediating Role of Amygdala Activity Recruiting NCT02824627 Phase 2 Oxytocin;Placebo
27 Intervening Early With Neglected Children: Key Childhood Outcomes Active, not recruiting NCT02093052 Phase 1, Phase 2
28 Investigating the Impact of Methylphenidate on Neural Response in Disruptive Behavioral Disorder Withdrawn NCT02247986 Phase 1, Phase 2 Methylphenidate Hydrochloride
29 Treatment of Youth Comorbid Conduct Problems and Depression Unknown status NCT01267773 Phase 1
30 A Phase 1, Single-dose, Sequential Cohort, Nonrandomized Crossover Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Oral Brexpiprazole in Children (6 to< 13 Years Old) With Central Nervous System Disorders Completed NCT03292848 Phase 1 Brexpiprazole
31 A Clinic-based Program for Families of Depressed Mothers Completed NCT00149812 Phase 1
32 Clinical Trajectory of Children and Adolescents With Disruptive Behavior Admitted to Pediatric and Psychiatric Emergencies. Unknown status NCT02828969
33 Parent Management Training to Prevent Oppositional Defiant and Conduct Disorders in Preschool Children Unknown status NCT00189189
34 Group-based Parenting Program "Incredible Years" to Reduce Child Conduct Disorder Symptoms in Families With Child Protection and Other Family Support Services in Finland Unknown status NCT03239990
35 Intergenerational Transmission of Antisocial Behavior Unknown status NCT00060788
36 Prevention and Reduction of Alcohol and Drug Problems in a Clinical Psychiatric Youth Population Unknown status NCT01595568
37 Epidemiological Study for Psychiatric Disorder Among Children and Adolescents Unknown status NCT02707848
38 A Randomized Controlled Trial of a Behavior Modification Toolkit in Primary School Children With ADHD Behaviors Unknown status NCT01330849
39 A School-Based Intervention to Improve Social Functioning in Children and Adolescents With ADHD: A Pragmatic Randomized Controlled Trial Comparing Standard and Enriched Provision. Unknown status NCT03313349
40 Assessment of the Impact of a Teaching Curriculum on Disruptive Behavior Disorders in Children and Youth: A Pilot Study Unknown status NCT03151187
41 Investigation of Psychophysiological Correlation of Aggression and Response to Aversive Stimuli Completed NCT03725371
42 On-line Treatment for Conduct Problems Completed NCT01822392
43 A Nutritional and Social Skills Intervention on Conduct Disorder and Hyperactivity Completed NCT00819429
45 Effectiveness of Parenting Intervention for Improving Child Mental Health: Randomised Single Blind Controlled Trial Completed NCT03905785
46 Investigation of Psychophysiological Response to Aversive Stimuli Over Time With Omega-3 Completed NCT03749824
47 Investigating the Neuro-Cognitive Underpinnings of the Emotional Dysfunction Linked to Childhood Behavioral Disturbance Completed NCT00104039
48 Can a Physical Activity Program Implemented at a Therapeutic School Promote Emotional Regulation and School Success in Socially and Emotionally Vulnerable Children? Completed NCT02766101
49 Designing a Novel Behavioral Treatment Protocol for Children Characterized by Conduct Problems and Callous-unemotional Traits Completed NCT01362946
50 The Effectiveness of Parent-Child Interaction Therapy (PCIT) in Treating Behavior Problems in Young Children Completed NCT01085305

Search NIH Clinical Center for Conduct Disorder

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Lithium Aspartate
Lithium Carbonate
lithium citrate

Cochrane evidence based reviews: conduct disorder

Genetic Tests for Conduct Disorder

Anatomical Context for Conduct Disorder

MalaCards organs/tissues related to Conduct Disorder:

Brain, Testes, Cortex, Amygdala, Heart, Eye, Cingulate Cortex

Publications for Conduct Disorder

Articles related to Conduct Disorder:

(show top 50) (show all 3892)
# Title Authors PMID Year
Variation in the catechol-O-methyltransferase Val 158 Met polymorphism associated with conduct disorder and ADHD symptoms, among adolescent male delinquents. 61 54
19997043 2010
Associations of the DRD2 TaqIA polymorphism with impulsivity and substance use: preliminary results from a clinical sample of adolescents. 54 61
19344737 2009
Genetic risk for conduct disorder symptom subtypes in an ADHD sample: specificity to aggressive symptoms. 61 54
19465875 2009
Monoamine oxidase A and childhood adversity as risk factors for conduct disorder in females. 54 61
18752729 2009
Is fetal brain monoamine oxidase inhibition the missing link between maternal smoking and conduct disorders? 61 54
18592036 2008
Case-control and within-family tests for an association between conduct disorder and DAT1. 54 61
18197081 2008
Testing for gene x environment interaction effects in attention deficit hyperactivity disorder and associated antisocial behavior. 54 61
17579368 2008
Adolescent conduct disorder and interpersonal callousness as predictors of psychopathy in young adults. 61 54
17658978 2007
A gene x gene interaction between DRD2 and DRD4 is associated with conduct disorder and antisocial behavior in males. 61 54
17587443 2007
COMT Val108/158Met gene variant, birth weight, and conduct disorder in children with ADHD. 54 61
17075359 2006
MAOA and the "cycle of violence:" childhood abuse and neglect, MAOA genotype, and risk for violent and antisocial behavior. 54 61
16814261 2006
Interaction between MAO-A genotype and maltreatment in the risk for conduct disorder: failure to confirm in adolescent patients. 61 54
16741202 2006
Gene-environment interaction in hyperkinetic conduct disorder (HD + CD) as indicated by season of birth variations in dopamine receptor (DRD4) gene polymorphism. 61 54
15288435 2004
Childhood adversity, monoamine oxidase a genotype, and risk for conduct disorder. 54 61
15237086 2004
Associations of the serotonin transporter promoter polymorphism with aggressivity, attention deficit, and conduct disorder in an adoptee population. 61 54
12658617 2003
Two dopamine genes related to reports of childhood retrospective inattention and conduct disorder symptoms. 61 54
11443528 2001
Dopamine D2 receptor gene (DRD2) is associated with alcoholism with conduct disorder. 61 54
11236830 2001
A dinucleotide repeat polymorphism at the gene for monoamine oxidase A and measures of aggressiveness. 54 61
8771218 1995
Serum dopamine beta hydroxylase and maltreatment in psychiatrically hospitalized boys. 54 61
7583738 1995
Genetic factors in substance abuse based on studies of Tourette syndrome and ADHD probands and relatives. I. Drug abuse. 54 61
8082550 1994
Low dopamine-beta-hydroxylase: a biological sequela of abuse and neglect? 61 54
1771204 1991
Feasibility of decision rule-based treatment of comorbid youth: A pilot randomized control trial. 61
32353635 2020
Antisocial Alcoholism in Parents of Adolescents and Young Adults With Childhood ADHD. 61
27895188 2020
Cannabis Use and Internalizing/Externalizing Symptoms in Youth: A Canadian Population-Based Study. 61
32115324 2020
The Bifactor S-1 Model: a Psychometrically Sounder Alternative to Test the Structure of ADHD and ODD? 61
32285353 2020
Latent classes of lifetime drug use disorder in national epidemiological survey on alcohol and related conditions - III. 61
32199206 2020
ADHD in Childhood and/or Adulthood as a Risk Factor for Domestic Violence or Intimate Partner Violence: A Systematic Review. 61
25995243 2020
ADHD and Psychiatric Comorbidity: Functional Outcomes in a School-Based Sample of Children. 61
26610741 2020
Screened Attention Deficit/Hyperactivity Disorder as a Predictor of Substance Use Initiation and Escalation in Early Adulthood and the Role of Self-Reported Conduct Disorder and Sensation Seeking: A 5-Year Longitudinal Study with Young Adult Swiss Men. 61
32564034 2020
GRM8 genotype is associated with externalizing disorders and greater inter-trial variability in brain activation during a response inhibition task. 61
32299001 2020
Conduct disorder and attention-deficit/hyperactivity disorder as risk factors for prescription opioid use. 61
32559668 2020
Cumulative incidence and relative risk of sleep problems among children and adolescents with newly diagnosed neurodevelopmental disorders: A nationwide register-based study. 61
32564480 2020
The role of effortful control in the development of ADHD, ODD, and CD symptoms. 61
30920279 2020
Prevalence and Correlates of Sexting Behaviors in a Provincially Representative Sample of Adolescents. 61
31835912 2020
Callous-Unemotional Traits and Risk of Gun Carrying and Use During Crime. 61
32539529 2020
Genetic Associations Between Executive Functions and a General Factor of Psychopathology. 61
31102652 2020
Initial Investigation of the Psychometric Properties of the Limited Prosocial Emotions Questionnaire (LPEQ). 61
32495674 2020
Psychiatric Disorders in the Adolescent Offspring of Mothers with Thyroid Problems During Pregnancy. 61
32008126 2020
Empathic Accuracy in Female Adolescents with Conduct Disorder and Sex Differences in the Relationship Between Conduct Disorder and Empathy. 61
32488571 2020
Positive and negative parenting in conduct disorder with high versus low levels of callous-unemotional traits. 61
32571444 2020
Five-Year Follow-Up for Adolescents With Conduct Disorder Referred to an Urgent Psychiatric Consult Clinic: A Descriptive Study. 61
32510877 2020
Adolescent-Parent Agreement on Callous-Unemotional Traits in Adolescents with Attention-Deficit/Hyperactivity Disorder. 61
32486294 2020
A Family-Based Genome Wide Association Study of Externalizing Behaviors. 61
32239439 2020
Prevalence estimates of mental health problems in children and adolescents with intellectual disability: A systematic review and meta-analysis. 61
32475125 2020
Sleep problems and associations with psychopathology and cognition in young people with 22q11.2 deletion syndrome (22q11.2DS). 61
31144615 2020
Do Implicit and Explicit Racial Biases Influence Autism Identification and Stigma? An Implicit Association Test Study. 61
32415531 2020
Brief Report: Can a Composite Heart Rate Variability Biomarker Shed New Insights About Autism Spectrum Disorder in School-Aged Children? 61
32449059 2020
The role of therapeutic alliance in therapy for adults with problematic aggression and associated disorders. 61
32410318 2020
Parent concerns: Differentiating developmental diagnoses in young children. 61
32454302 2020
The Associations Between Pre- and Postnatal Maternal Symptoms of Distress and Preschooler's Symptoms of ADHD, Oppositional Defiant Disorder, Conduct Disorder, and Anxiety. 61
26647350 2020

Variations for Conduct Disorder

Expression for Conduct Disorder

Search GEO for disease gene expression data for Conduct Disorder.

Pathways for Conduct Disorder

Pathways related to Conduct Disorder according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
11.84 SLC6A3 MAOA DRD2
7 11.82 TPH1 SLC6A4 MAOA
Show member pathways
11.79 DRD5 DRD4 DRD2
Show member pathways
10 11.67 TPH1 MAOA DBH
Show member pathways
Show member pathways
Show member pathways
14 11.03 TPH1 SLC6A4 MAOA
15 10.9 POMC DRD2
Show member pathways
Show member pathways
18 10.71 MAOA COMT
Show member pathways
Show member pathways
10.66 MAOA ALDH2
Show member pathways
22 10.45 MAOA ALDH2

GO Terms for Conduct Disorder

Cellular components related to Conduct Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.56 SLC6A4 SLC6A3 OXTR NTSR2 GABRA2 DRD5
2 integral component of membrane GO:0016021 9.47 SLC6A4 SLC6A3 OXTR NTSR2 NBAS MYRFL
3 integral component of presynaptic membrane GO:0099056 9.43 SLC6A4 SLC6A3 DRD2
4 integral component of postsynaptic membrane GO:0099055 9.33 SLC6A4 SLC6A3 DRD2
5 dopaminergic synapse GO:0098691 9.32 SLC6A3 DRD2

Biological processes related to Conduct Disorder according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.92 GABRA2 DRD5 DRD4 DBH
2 response to drug GO:0042493 9.89 SLC6A4 SLC6A3 OXTR DRD2 COMT
3 response to organic cyclic compound GO:0014070 9.84 SLC6A3 OXTR COMT
4 locomotory behavior GO:0007626 9.81 SLC6A3 DRD2 DBH
5 memory GO:0007613 9.8 SLC6A4 OXTR DBH
6 social behavior GO:0035176 9.73 SLC6A4 OXTR DRD4
7 neurotransmitter transport GO:0006836 9.7 SLC6A4 SLC6A3 GABRA2
8 response to pain GO:0048265 9.66 DBH COMT
9 behavioral response to cocaine GO:0048148 9.66 DRD4 DRD2
10 response to iron ion GO:0010039 9.65 SLC6A3 DRD2
11 negative regulation of voltage-gated calcium channel activity GO:1901386 9.65 DRD4 DRD2
12 prepulse inhibition GO:0060134 9.65 SLC6A3 DRD2
13 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.64 DRD5 DRD2
14 neurotransmitter biosynthetic process GO:0042136 9.64 SLC6A4 SLC6A3
15 maternal behavior GO:0042711 9.63 OXTR DBH
16 catecholamine metabolic process GO:0006584 9.61 MAOA COMT
17 neurotransmitter catabolic process GO:0042135 9.61 MAOA COMT
18 associative learning GO:0008306 9.61 DRD5 DRD2 DBH
19 regulation of dopamine metabolic process GO:0042053 9.6 SLC6A3 DRD4
20 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.59 DRD4 DRD2
21 adenohypophysis development GO:0021984 9.58 SLC6A3 DRD2
22 monoamine transport GO:0015844 9.58 SLC6A4 SLC6A3
23 dopamine receptor signaling pathway GO:0007212 9.58 DRD5 DRD4 DRD2
24 hyaloid vascular plexus regression GO:1990384 9.57 SLC6A3 DRD2
25 sperm ejaculation GO:0042713 9.55 SLC6A4 OXTR
26 regulation of systemic arterial blood pressure by vasopressin GO:0001992 9.54 OXTR DRD5
27 synaptic transmission, dopaminergic GO:0001963 9.54 DRD5 DRD4 DRD2
28 fear response GO:0042596 9.51 DRD4 DBH
29 behavioral response to ethanol GO:0048149 9.5 DRD4 DRD2 DBH
30 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.48 DRD4 DRD2
31 response to histamine GO:0034776 9.46 DRD4 DRD2
32 response to cocaine GO:0042220 9.46 SLC6A3 OXTR DRD5 DRD2
33 dopamine metabolic process GO:0042417 9.43 DRD4 DRD2 COMT
34 dopamine catabolic process GO:0042420 9.26 SLC6A3 MAOA DBH COMT
35 response to amphetamine GO:0001975 9.02 OXTR DRD5 DRD4 DRD2 DBH

Molecular functions related to Conduct Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 9.5 SLC6A3 DRD4 DRD2
2 neurotransmitter:sodium symporter activity GO:0005328 9.4 SLC6A4 SLC6A3
3 adrenergic receptor activity GO:0004935 9.37 DRD5 DRD2
4 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.26 DRD4 DRD2
5 monoamine transmembrane transporter activity GO:0008504 9.16 SLC6A4 SLC6A3
6 dopamine neurotransmitter receptor activity GO:0004952 9.13 DRD5 DRD4 DRD2
7 dopamine binding GO:0035240 8.92 SLC6A3 DRD5 DRD4 DRD2

Sources for Conduct Disorder

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....